A Call For More Research On Cancer’s Environmental Triggers
No question about cancer is more contentious than its causes.
writer, patient advocate, physician
No question about cancer is more contentious than its causes.
These results have the potential to reduce overtreatment of breast cancer—stopping patients’ unnecessary exposure to chemotherapy—in a large fraction of cases.
For patients with metastatic breast cancer, doctors don’t yet know how to predict long-term responses to this PARP drug.
What’s at issue is the right of all cancer patients—regardless of wealth—to obtain high-quality information about their conditions.
Few doctors, even oncologists who subspecialize, can keep up with developments in the field.
The paradigm for using chemo first to treat advanced breast cancer may change, as we gain experience with these new drugs.
Before choosing any treatment after genetic testing, hit the pause button. Ask questions. Get a second opinion.
Perhaps the literature fails to capture the clinical value of oncology drugs. This could happen for several reasons.
A new type of cancer medication, called PARP inhibitors, is gaining traction in clinical practice.
I hope for the future that other brilliant minds will have found and implemented ways to prevent most breast cancers, established accurate methods to detect it early, and developed better treatments, aimed at cures.
“Medicine is rapidly falling behind business in the accrual of high-quality evidence,” Califf said.
“This tool brings us closer to the country doctor model,” Basch said. “I never thought that survival would be impacted.”
The key to the positive results is molecular matching. Patients received larotrectinib, a TRK inhibitor, only if their cancers were marked by a switch…It’s a perfect example of how precision medicine can benefit patients with rare conditions.
The FDA’s accelerated approval of this drug might surprise traditional oncologists. It suggests the agency may be ditching an archaic system for classifying cancers based on body parts—like breast or liver or colon cancer—and instead will focus..
My enthusiasm for this new drug, Stivarga, is tempered by the low response rate and toxicity.
It’s possible that tumor mutation burden (TMB) predicts if cancer―of any type―will respond to treatment with immune drugs, but this remains to be tested.
Lynparza—a PARP inhibitor taken as an oral tablet, daily— keeps qualified cases of advanced ovarian cancer in check for two years, as compared to placebo.
My worry for Grail is that a lot of people will get worked up upon finding genetic changes of unknown significance. Meanwhile, it might fail to detect cancer in people who really have it.
We need and can afford both: to raise the bar so that everyone has access to modern healthcare, and to advance treatments through medical science.
The Cures Act will keep the U.S. at the forefront of medical progress, a draw for scientists and doctors around the world, a source of pride.
Ribociclib is one of several CDK inhibitors being tried in breast cancer and other malignancies.
The FDA’s decision reflects a thoughtful, not knee-jerk approach to its mission, which is to protect the public from fraudulent and unsafe substances. What’s at issue is how well eteplirsen works. And that it’s too expensive.
It was a seemingly innocuous change in the protocol that may have caused this experimental tragedy. Which is all the more reason to be careful, and mind the details.
If these data pan out, this first-in-class antibody might be likened to Herceptin, or Rituxan… a precise treatment that works on malignant cells that have tested positive for the relevant molecule.
“If we had a drug that caused this level of survival benefit, wouldn’t we want to go out and use it?” said Dr. Patricia Ganz.
This paper offers the clearest demonstration, yet, of the value – to patients – of precision medicine in oncology.
The potential to reduce overtreatment, in women with a low chance of recurrence for which chemo is unlikely to be of benefit, is huge.
Today, Walter White might not be doomed by his lung cancer. The harder problem is how to pay for his care.
Evaluation of circulating tumor cells enables monitoring of some cancers from blood samples. This form of liquid biopsy offers…
Tomorrow’s doctors need to grasp more concepts in science and technology than did any previous generation of physicians.
Blood specialists reported on practice-changing studies for sickle cell disease, including a large study of bone marrow transplant from matched sibling donors. A preliminary report looked at effects of GBT440, a novel oral agent that augments hemoglobin’s binding to oxygen.
Venetoclax is a powerful new kind of oral medication. It enables leukemia cells to die by interfering with Bcl-2, a survival signal.
If there’s one thing that’s become clear about precision medicine – and the delivery of optimal care based in science – it will require super technology. This need is especially urgent in oncology.
These biomarkers should link patients to optimal therapy (when such exists), and lead some to decline therapy that’s unlikely to help. The CDx field is moving forward rapidly in oncology..
A common misconception is that precision medicine is about one drug for one disease. But for most cancer types, it will involve combining medications in effective cocktails.
Over time, the costs should drop, like for smartphone tech, what my Dad – a chemistry major and retired physician – called “magic.”